Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1994 1
1995 1
2000 1
2001 1
2002 1
2006 1
2009 1
2011 1
2012 1
2014 5
2015 1
2016 2
2017 1
2018 2
2019 3
2020 6
2021 4
2022 6
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Biliary Tract Carcinoma"
Page 1
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D. Banales JM, et al. Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80. doi: 10.1038/nrgastro.2016.51. Epub 2016 Apr 20. Nat Rev Gastroenterol Hepatol. 2016. PMID: 27095655 Free article.
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late d …
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the s …
Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment.
Bragazzi MC, Venere R, Ribichini E, Covotta F, Cardinale V, Alvaro D. Bragazzi MC, et al. Dig Liver Dis. 2024 Mar;56(3):383-393. doi: 10.1016/j.dld.2023.08.052. Epub 2023 Sep 16. Dig Liver Dis. 2024. PMID: 37722960 Review.
Intrahepatic cholangiocarcinoma is the second most frequent primary liver cancer after hepatocellular carcinoma. According to International Classification of Diseases-11 (ICD-11), intrahepatic cholangiocarcinoma is identified by a specific diagnostic code, different with r …
Intrahepatic cholangiocarcinoma is the second most frequent primary liver cancer after hepatocellular carcinoma. According to Interna …
Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH, Tan E, Kim R. Sahin IH, et al. Expert Opin Investig Drugs. 2021 Apr;30(4):333-341. doi: 10.1080/13543784.2021.1867537. Epub 2020 Dec 30. Expert Opin Investig Drugs. 2021. PMID: 33378249 Review.
AREAS COVERED: We discuss regorafenib, a multi-kinase inhibitor, which has been investigated as a therapeutic agent in advanced stage biliary tract cancer patients in phase II trials. We examined the efficacy and toxicity of this agent and its potential in this pati …
AREAS COVERED: We discuss regorafenib, a multi-kinase inhibitor, which has been investigated as a therapeutic agent in advanced stage bil …
Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T, Sakurai-Yageta M, Goto A, Pairojkul C, Yongvanit P, Murakami Y. Ito T, et al. J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):380-7. doi: 10.1002/jhbp.67. Epub 2014 Feb 13. J Hepatobiliary Pancreat Sci. 2014. PMID: 24532422 Review.
Cholangiocarcinoma (CCA) is one of the representative cancers refractory to any therapeutic approach. The incidence of CCA is highest in the northeastern part of Thailand, where chronic inflammation caused by liver fluke (Opisthorchis viverrini: Ov) infection is a major et …
Cholangiocarcinoma (CCA) is one of the representative cancers refractory to any therapeutic approach. The incidence of CCA is highest …
Community Awareness and Education: In the West and Southeast Asia.
Morement H, Khuntikeo N. Morement H, et al. Recent Results Cancer Res. 2023;219:349-359. doi: 10.1007/978-3-031-35166-2_12. Recent Results Cancer Res. 2023. PMID: 37660339
The incidence is increasing globally, and mortality is high owing to its aggressiveness, late diagnosis, and refractory nature. In this chapter, the awareness of cholangiocarcinoma in the West and in Southeast Asia, particularly Thailand, is explored. ...
The incidence is increasing globally, and mortality is high owing to its aggressiveness, late diagnosis, and refractory nature. In th …
Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.
Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Dondossola D, et al. World J Gastroenterol. 2020 Jul 7;26(25):3542-3561. doi: 10.3748/wjg.v26.i25.3542. World J Gastroenterol. 2020. PMID: 32742125 Free PMC article. Review.
Cholangiocarcinoma (CCC) is the most aggressive malignant tumor of the biliary tract. Perihilar CCC (pCCC) is the most common CCC and is burdened by a complicated diagnostic iter and its anatomical location makes surgical approach burden by poor results. ...Consiste …
Cholangiocarcinoma (CCC) is the most aggressive malignant tumor of the biliary tract. Perihilar CCC (pCCC) is the most common …
Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T, Zheng S, Geng L, Liu Z, Xu J, Lin B, Qian J, Zheng S. Shen T, et al. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820979703. doi: 10.1177/1533033820979703. Technol Cancer Res Treat. 2020. PMID: 33308041 Free PMC article. Review.
BACKGROUND: Novel immunotherapy is one of the options for advanced biliary tract cancer (BTC) patients who are traditionally intolerant to chemotherapy. However, clinical evidence for single immunotherapy with pembrolizumab or nivolumab is limited. ...This initial a …
BACKGROUND: Novel immunotherapy is one of the options for advanced biliary tract cancer (BTC) patients who are traditionally i …
Recent advances in endoscopic ultrasonography.
Nakazawa S. Nakazawa S. J Gastroenterol. 2000;35(4):257-60. doi: 10.1007/s005350050342. J Gastroenterol. 2000. PMID: 10777153 Review.
Endoscopic ultrasonography is recognized as an important tool in the diagnosis and staging of esophageal, gastric, colorectal, pancreatic, and biliary tumors. It also is a reliable method for the evaluation of submucosal tumors of the gastrointestinal tract, the dif …
Endoscopic ultrasonography is recognized as an important tool in the diagnosis and staging of esophageal, gastric, colorectal, pancreatic, a …
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Chakrabarti S, et al. Oncologist. 2020 May;25(5):380-e763. doi: 10.1634/theoncologist.2019-0874. Epub 2019 Dec 11. Oncologist. 2020. PMID: 31826977 Free PMC article. Clinical Trial.
LESSONS LEARNED: Trifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary tract carcinoma, including patients with 5-fluorouracil refractory tumors. FTD/TPI has an acceptable safety profil …
LESSONS LEARNED: Trifluridine/tipiracil (FTD/TPI) shows promising antitumor activity in heavily pretreated patients with advanced biliary …
Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine.
Ikeda M, Ioka T, Fukutomi A, Morizane C, Kasuga A, Takahashi H, Todaka A, Okusaka T, Creasy CL, Gorman S, Felitsky DJ, Kobayashi M, Zhang F, Furuse J. Ikeda M, et al. Cancer Sci. 2018 Jan;109(1):215-224. doi: 10.1111/cas.13438. Epub 2017 Dec 9. Cancer Sci. 2018. PMID: 29121415 Free PMC article. Clinical Trial.
Gemcitabine-based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second-line treatment(s) established yet. Aberrant activation of the MAPK pathway in patients with BTC indicates its importance in BTC. ...Twenty patie …
Gemcitabine-based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second-line …
35 results